NYSE:TARO - Taro Pharmaceutical Industries Stock Price, Price Target & More

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced its quarterly earnings results on Thursday, May, 17th. The company reported $2.17 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.51 by $0.66. The business had revenue of $175.22 million for the quarter, compared to analyst estimates of $166.59 million. Taro Pharmaceutical Industries had a return on equity of 11.33% and a net margin of 31.90%. View Taro Pharmaceutical Industries' Earnings History.

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Taro Pharmaceutical Industries.

1 equities research analysts have issued 12-month target prices for Taro Pharmaceutical Industries' shares. Their predictions range from $130.00 to $130.00. On average, they anticipate Taro Pharmaceutical Industries' stock price to reach $130.00 in the next year. This suggests a possible upside of 12.3% from the stock's current price. View Analyst Ratings for Taro Pharmaceutical Industries.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Taro Pharmaceutical Industries include UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS) and Catalent (CTLT).

News headlines about TARO stock have trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Taro Pharmaceutical Industries earned a daily sentiment score of 0.13 on Accern's scale. They also assigned press coverage about the company an impact score of 46.76 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Taro Pharmaceutical Industries' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Empirical Finance LLC (0.03%) and Hudson Capital Management LLC (0.02%). View Institutional Ownership Trends for Taro Pharmaceutical Industries.

TARO stock was sold by a variety of institutional investors in the last quarter, including Empirical Finance LLC. View Insider Buying and Selling for Taro Pharmaceutical Industries.

TARO stock was purchased by a variety of institutional investors in the last quarter, including Hudson Capital Management LLC. View Insider Buying and Selling for Taro Pharmaceutical Industries.

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TARO stock can currently be purchased for approximately $115.73.

Taro Pharmaceutical Industries has a market capitalization of $4.56 billion and generates $661.91 million in revenue each year. The company earns $211.15 million in net income (profit) each year or $6.18 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,413 workers across the globe.

Taro Pharmaceutical Industries' mailing address is 14 HAKTOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]